High-risk melanoma with nodal involvement in a young woman

被引：0
|
作者：
Omar Khan
Mark Middleton
机构：
[1] a trainee oncologist,
[2] a consultant in Medical Oncology at the University of Oxford Cancer Research UK Medical Oncology Unit,undefined
[3] Churchill Hospital,undefined
来源：
Nature Clinical Practice Oncology | 2006年 / 3卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Background An 18-year-old female presented to her General Practitioner with a bleeding mole on her back. The mole had been present since childhood but had started to bleed in the past month. She was otherwise asymptomatic with no relevant previous medical history. Physical examination revealed a 1.5 cm × 1.7 cm pigmented lesion on the left aspect of the patient's upper back. There was no palpable lymphadenopathy.
引用
收藏
页码：517 / 521
页数：4
相关论文
共 50 条
  • [41] ADJUVANT CHEMOTHERAPY IN HIGH-RISK MALIGNANT-MELANOMA
    KARAKOUSIS, CP
    EMRICH, LJ
    CANCER DRUG DELIVERY, 1986, 3 (01): : 86 - 86
  • [42] Systemic adjuvant therapy for high-risk cutaneous melanoma
    Kobeissi, Iyad
    Tarhini, Ahmad A.
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2022, 14
  • [43] Screening for melanoma in high-risk patients: Useful or useless?
    Eaton, K. D.
    Sax, K.
    Lamerson, C.
    JOURNAL OF INVESTIGATIVE MEDICINE, 2008, 56 (01) : 249 - 249
  • [44] Adjuvant Interferon in High-Risk Melanoma: End of the Era?
    Janku, Filip
    Kurzrock, Razelle
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (02) : E15 - E16
  • [45] The adjuvant treatment revolution for high-risk melanoma patients
    Spagnolo, Francesco
    Boutros, Andrea
    Tanda, Enrica
    Queirolo, Paola
    SEMINARS IN CANCER BIOLOGY, 2019, 59 : 283 - 289
  • [46] Adjuvant polypeptide vaccines for high-risk uveal melanoma
    Gaughan, Elizabeth Mary
    Lucchesi, Nicholas
    Jin, Ruyun
    Slingluff, Craig L.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [47] Optimal systemic therapy for high-risk resectable melanoma
    Eggermont, Alexander M. M.
    Hamid, Omid
    Long, Georgia, V
    Luke, Jason J.
    NATURE REVIEWS CLINICAL ONCOLOGY, 2022, 19 (07) : 431 - 439
  • [48] Neoadjuvant immunotherapy improves outlook in high-risk melanoma
    Nierengarten, Mary Beth
    CANCER, 2023, 129 (13) : 1952 - 1952
  • [49] Finally, a successful adjuvant therapy for high-risk melanoma
    Balch, CM
    Buzaid, AC
    JOURNAL OF CLINICAL ONCOLOGY, 1996, 14 (01) : 1 - 3
  • [50] Optimal systemic therapy for high-risk resectable melanoma
    Alexander M. M. Eggermont
    Omid Hamid
    Georgia V. Long
    Jason J. Luke
    Nature Reviews Clinical Oncology, 2022, 19 : 431 - 439
12345